Hypoxia-mediated apoptosis in oral carcinoma cells occurs via two independent pathways by Nagaraj, Nagathihalli S et al.
BioMed  Central
Page 1 of 14
(page number not for citation purposes)
Molecular Cancer
Open Access Research
Hypoxia-mediated apoptosis in oral carcinoma cells occurs via two 
independent pathways
Nagathihalli S Nagaraj1, Nadarajah Vigneswaran3 and Wolfgang Zacharias*1,2
Address: 1Department of Medicine, James Graham Brown Cancer Center, University of Louisville, Louisville, Kentucky 40202, USA, 2Department 
of Pharmacology & Toxicology, University of Louisville, Louisville, Kentucky 40202, USA and 3Department of Diagnostic Sciences, The University 
of Texas Health Science Center at Houston, Dental Branch, Houston, Texas 77030, USA
Email: Nagathihalli S Nagarajah - nsnaga01@gwise.louisville.edu; Nadarajah Vigneswaran - Nadarajah.Vigneswaran@uth.tmc.edu; 
Wolfgang Zacharias* - w0zach01@gwise.louisville.edu
* Corresponding author    
Abstract
Background: We are attempting to elucidate the mechanism of apoptotic cell death induced by
hypoxia in oral cancer cells. Since hypoxia can render solid tumors more resistant to radiation and
chemotherapy, understanding the pathways involved in hypoxia-induced apoptosis of oral cancer
cells would be of significant therapeutic value.
Results: Here we showed that oral cancer cells from primary tumor and lymph node metastasis
undergo apoptosis after 24 to 48 h of hypoxia. During hypoxic growth, an increase in caspase-3
proteolytic activity was observed, accompanied by the cleavage of PARP (poly (ADP-ribose)
polymerase) indicative of caspase activity. In addition, hypoxic stress also lead to activation of
caspase-8, -9, and -10 but not -1, elicited the release of cytochrome C into the cytosol, and resulted
in internucleosomal DNA fragmentation.
Conclusion: These results show that hypoxia-induced apoptosis in oral carcinoma cell lines relies
on both intrinsic (mitochondrial) and extrinsic (cell death receptor mediated) pathways. This novel
evidence will assist in designing more efficient combination chemotherapy approaches as promising
strategy for the treatment of oral cancers.
Background
Oral cancer is one of the 10 most frequently occurring
cancers worldwide, and its incidence in Europe and the
United States ranges from 2% to 6% among all cancer
patients [1,2]. The 5-year survival rate of less than 50%
has not substantially improved over the past several dec-
ades, since many oral carcinomas respond poorly to
chemotherapy approaches and their responses to radia-
tion therapy have been highly variable.
Hypoxia, a reduction in the level of tissue oxygen tension,
occurs during acute and chronic vascular disease, pulmo-
nary disease and cancer, and can lead to apoptotic or
necrotic cell death [3,4]. Fast growing tumors become
hypoxic because newly developed blood vessels are ineffi-
cient and have poor blood flow. Although hypoxia is toxic
to both cancer cells and normal cells, tumor cells can
undergo genetic and adaptive changes in response to
hypoxia that allow them to survive and proliferate [5].
Thus, hypoxic growth can result in a tumor with more
aggressive growth characteristics and more malignant
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phenotype [3]. Although micro-environmental irregulari-
ties in solid tumors have been well documented, little is
known about how different types of tumor cell pheno-
types tolerate and respond to these conditions.
Apoptotic cell death is controlled by pro-apoptotic cas-
pases, proteases that are synthesized as inactive precursors
and activated by proteolytic processing [6]. The apoptotic
cascade can be initiated via two major pathways, involv-
ing either the release of cytochrome C from the mitochon-
dria (mitochondrial pathway) [7] or activation of death
receptors in response to ligand binding (death receptor
pathway) [8]. Upon triggering of either pathway, caspases,
the final executioners of apoptosis, are activated, causing
degradation of cellular proteins and leading to typical
morphological changes such as chromatin condensation,
nuclear shrinkage, and the formation of apoptotic bodies
[9]. Both pathways are differentially involved in the cellu-
lar response to diverse apoptotic stimuli [10,11]. The
majority of chemotherapeutic agents trigger the mito-
chondrial pathway, but the death receptors have also been
reported to be involved in chemotherapy-induced apop-
tosis [12].
Death ligands such as TNF-α or CD95L recruit, via the
adapter molecule FADD, cytoplasmic monomeric initia-
tor caspase-8 to their surface receptors, resulting in dimer-
ization and activation of caspase-8 [13,14]. Active
caspase-8 cleaves and activates downstream effector cas-
pases including caspase-3, -6 or -7, which degrade a broad
range of cellular proteins and trigger the appearance of the
apoptotic morphology [6,15]. On the other hand, mito-
chondria are important regulatory sites of the apoptotic
process [16]. Defects in mitochondrial function result in
release of cytochrome C, which can associate with Apaf-1
(apoptosis protease activating factor) and pro-caspase-9.
The observation that chemical inhibition of caspase-9
blocks hypoxia-induced apoptosis points to a role of the
complex in hypoxia-induced apoptosis [17,18]. This acti-
vation complex results in auto-processing of caspase-9
and further activation of downstream caspases, such as
caspase-3 [19,20]. Activation of caspase-3 has been linked
to the proteolytic cleavage of cellular substrates including
poly-ADP-ribose-polymerase (PARP) [21], and is also
necessary for the nuclear changes and chromatin conden-
sation associated with apoptosis [22].
The low oxygen tension in hypoxic tumors is known to
interfere with the efficacy of chemotherapy or radiother-
apy. Also, hypoxia-induced apoptosis may impose a selec-
tion pressure favoring growth of more resistant tumor
cells. However, the factors leading to hypoxia-induced
apoptosis and their relative contribution to intrinsic and
extrinsic apoptotic pathways are not well characterized. In
the present study, we determined which factors in the
mitochondria-dependent and -independent apoptosis
pathways are activated in oral cancer cells. We observed
that hypoxia-induced apoptotic cell death occurs through
activation of caspase 8, but also cytochrome C release, cas-
pase-9 activation, and results in caspase 3 processing,
PARP cleavage, and DNA fragmentation. These results
suggest that hypoxia-induced apoptosis in oral carcino-
mas cells relies on both intrinsic (mitochondrial) and also
extrinsic (cell death receptor mediated) pathways.
Results
Hypoxia condition
Direct measurements of oxygen tensions in human
tumors show a range of median oxygen tensions from 1.3
to 3.9 % (10–30 mm Hg), with readings recorded as low
as 0.01 % (0.08 mm Hg) under severe hypoxia, whereas
in normal tissues O2 levels can range from 3.1 to 8.7 %
(24–66 mm Hg) [25]. Severe hypoxia stimulates cells to
undergo apoptosis, whereas oxygen levels above 0.5 %
prevent cell death, indicating tight regulation of cellular
responses to the microenvironment. Critical O2  levels
(hypoxic thresholds) characterize the upper limit of the
hypoxic range below which activities and functions pro-
gressively become restricted. These levels can encompass
O2 partial pressures from 35 mm Hg (start of reduced cell
death in conventional photodynamic therapy or restricted
efficacy of some immunotherapy) to 0.02 mm Hg; below
this level, cytochromes aa3 and c are no longer fully oxi-
dized [25]. During severe hypoxia or anoxia, a cascade of
events is initiated that leads to global apoptotic cell death,
thereby preventing the accumulation of cells with
hypoxia-induced regulatory responses or mutations [26].
Thus, a condition of less severe hypoxia (1 %) was chosen
to be able to monitor the response of viable cells under
this condition.
Morphological changes and DNA fragmentation during 
hypoxia
Trypan Blue dye exclusion was used to quantitate the
number of viable cells after 24 and 48 h of hypoxia.
TUNEL assays were used to visualize apoptotic cells, and
DNA fragmentation into oligonucleosome-sized frag-
ments, indicative of apoptotic cellular death, was moni-
tored by gel electrophoresis [27]. The percentage of viable
cells was steadily reduced in hypoxia-treated cells com-
pared to normoxic control cells (Figure 1). Whereas
approximately 5 – 15 % reduction of viability was seen at
24 h, all hypoxic cell lines declined further at 48 h to 85 –
75 % viability compared to normoxic growth. Hypoxic
growth induced morphological alterations typical for
apoptotic cell death, as determined by TUNEL assays (Fig-
ure 2). The hypoxia-treated cells showed extensive nuclear
dye staining indicative for DNA breakage and cell death.
This effect was detectable at 24 h (data not shown) and
very apparent after 48 h of hypoxia, when most of theMolecular Cancer 2004, 3:38 http://www.molecular-cancer.com/content/3/1/38
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treated cells showed the typical morphology of apoptotic
nuclear condensation. In contrast, nuclear staining was
much weaker and less pronounced for normoxic cells up
to 48 h incubation. Hypoxic conditions induced the chro-
matin alterations typical for apoptotic cell death, as dem-
onstrated by fragmentation of chromosomal DNA into
nucleosomal DNA ladders (Figure 3). Exposure to
hypoxia for 24 or 48 h resulted in a time-dependent
increase in DNA fragmentation in all four oral cancer
cells, whereas no internucleosomal DNA fragmentation
was observed in the normoxic control cultures (Figure 3).
It is also apparent that the two metastatic lines 686Ln and
1386Ln had less extensive DNA fragmentation compared
to their respective primary tumor lines 686Tu and
1386Tu.
Processing of caspases, PARP cleavage and cytochrome C 
release
The effects of hypoxia treatment on activation of key cas-
pases and PARP in the four cell lines 686Tu/Ln and
1386Tu/Ln was determined by Western blotting using
antibodies that recognize both full-length and cleaved
proteins (Figures 4 and 5). Growth of cells under hypoxia
caused a time-dependent processing of caspase-3, -8 and -
9. For all four cell lines, hypoxia resulted in enhancement
of procaspase-3 (32 kD) cleavage into the two immunore-
active fragments of ~20 and ~11 kD at the 24 and 48 h
time points (Figures 4A and 5A). This treatment also
resulted in cleavage of the 47 kD procaspase-9 to yield
fragments of ~37 and ~20 kD, in parallel to caspase-3
cleavage (Figures 4C and 5C). Furthermore, caspase 8 was
present primarily as ~55 kD pro-form in normoxic cells,
whereas exposure to hypoxia resulted in its time-depend-
ent processing to the ~32 kD active form (Figures 4B and
5B). These observations point towards involvement of
both caspase-9 and caspase-8 in hypoxia-mediated cleav-
age of caspase-3 in all four cell lines. They suggest that a
cascade of caspase activation occurs through the mito-
chondrial and also through the cell death receptor path-
way in these cells in response to hypoxia.
To gain further insight into the role of mitochondria in
this process, the extent of cytochrome C release under
hypoxia was analyzed. Translocation of cytochrome C
from the mitochondria to the cytosol was detected in all
four cell lines after 24 h, and more pronounced after 48 h,
of hypoxia (Figures 4E and 5E). This release of
cytochrome C was a controlled event and not due to phys-
ical disruption of mitochondria, since no signal for intra-
mitochondrial cytochrome oxidase could be detected in
the same cytosolic fractions under these conditions (data
not shown). Thus, these results demonstrate that hypoxia
induced the release of cytochrome C from intact
mitochondria.
Since we observed that hypoxia activated caspase-3 in the
oral carcinoma cells, we investigated the cleavage of the
caspase-3 substrate PARP under hypoxic versus normal
growth. Clearly, cleavage of PARP, as indicated by a
decrease in the full-length 113 kD protein and appearance
of the 85 kD cleaved PARP product, was prominent in
hypoxic cells, whereas it was almost completely absent in
normoxia cells (Figures 4D and 5D). A small amount of
cleaved PARP was already found after 24 h hypoxic condi-
tions, and this effect was much more pronounced at 48 h.
Only very small amounts of PARP cleavage product could
be detected in the normoxic 1386 cell line pair, whereas
for the 686 pair PARP cleavage appeared undetectable.
Caspase activities during hypoxia-mediated apoptosis
As caspases are early effectors for triggering apoptosis,
assays to determine caspase enzymatic activities further
substantiated our findings that hypoxia-induced apopto-
sis occurs through both intrinsic (mitochondrial) and also
extrinsic (cell death receptor mediated) pathways. We
examined caspase proteolytic activities in cell extracts
using fluorogenic peptide substrates specific for individ-
ual caspases. These substrates are conjugated with AFC or
AMC and have aspartic acid residues at P1 positions, a
requirement for caspase proteolysis. Cleavage of these
substrates after the aspartic acid residue results in release
Viability assay for oral carcinoma cells under hypoxia Figure 1
Viability assay for oral carcinoma cells under hypoxia. The 
numbers of viable (Trypan blue-excluding) cells were deter-
mined after 24 or 48 hours, and the percent of viability of 
hypoxic cells plotted relative to normoxic control cells; via-
bilities under normoxia were 100% for all cells. The results 
show the mean (± SD) of three independent experiments. 
686Tu = open square; 686Ln = closed square; 1386Tu = 
open circle; 1386Ln = closed circle.Molecular Cancer 2004, 3:38 http://www.molecular-cancer.com/content/3/1/38
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Hypoxia-induced nuclear TUNEL staining in oral carcinoma cells Figure 2
Hypoxia-induced nuclear TUNEL staining in oral carcinoma cells. The cells were incubated for 48 h in hypoxic or normoxic 
conditions, and photographs were taken after TUNEL staining of cells with DAB. Few apoptotic nuclei were observed in nor-
moxic cells, but exposure to hypoxia for 48 h induced nuclear DNA condensation and fragmentation. Cells with nuclei showing 
strong chromatin condensation and nuclear fragmentation were considered apoptotic.
Effect of hypoxia on apoptosis induction as determined by DNA fragmentation Figure 3
Effect of hypoxia on apoptosis induction as determined by DNA fragmentation. Nucleosomal DNA fragments in 686 (A) and 
1386 (B) cells were analyzed by gel electrophoresis after 24 or 48 h hypoxia. Apoptosis was confirmed by the appearance of a 
ladder of oligonucleosomal DNA. M, molecular standard; P, positive DNA ladder control.Molecular Cancer 2004, 3:38 http://www.molecular-cancer.com/content/3/1/38
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of unbound AFC or AMC which can be monitored
fluorometrically.
Detergent extracts prepared from cells after exposure to
hypoxia or normoxia for either 24 or 48 h were tested for
caspase cleavage activities, and specific inhibitors for con-
trol measurements were used as described in Materials
and Methods. N-Ac-DEVD-AFC is cleaved by caspase-3
and -7, but may also be cleaved by other caspases, N-Ac-
YVAD-AFC is cleaved by caspase-1, N-Ac-IETD-AMC by
caspase-8, N-Ac-LEHD-AFC by caspase-9, and N-Ac-
AEVD-AFC by caspase-10. Activities of caspase-3, -8, -9
and -10 were clearly and consistently elevated during
hypoxia treatment for up to 48 h compared to normoxic
growth for the 686 (Figure 6) and 1386 (Figure 7) cell line
pairs. In contrast, only low caspase-1 activities were found
for all four cell lines in normoxic condition, and these
were not substantially altered after hypoxia challenge at
any of the times examined (Figures 6A and 7A).
Overall, significant induction of hypoxia-mediated cleav-
age activities for the N-Ac-DEVD-AFC, N-Ac-IETD-AMC
and N-Ac-LEHD-AFC substrates was detected in all four
cell extracts, and induction of these activities correlated
well with the levels observed for caspase-3, caspase-8 and
caspase-9 protein expression and processing. Thus, induc-
tion of apoptosis was preceded by the activation of activa-
tor caspase-8, initiating receptor-mediated apoptosis, and
caspase-9, initiating mitochondrial apoptosis, as well as
the effector caspase-3.
Effects of caspase inhibitors on caspase activity profile
We investigated the effects of individual cell-permeable
caspase inhibitors on caspase-3, -8 and -9 activities during
hypoxic growth for 48 hours (Figure 8). These inhibitors
can enter viable cells and are covalently and irreversibly
bound to their target caspases. Z-VAD-fmk was a pan-cas-
pase inhibitor for all caspases analyzed; z-DEVD-fmk was
inhibitor for caspase-3, z-LEHD-fmk for caspase-9, and z-
IETD-fmk for caspase-8 activity. The presence of Z-DEVD-
fmk clearly inhibited activity of its target protease caspase-
3, but not caspases 8 or 9. The pan-caspase inhibitor z-
VAD-fmk, as expected, diminished activities of all three
tested caspases. Z-LEHD-fmk as inhibitor for caspase 9 did
not affect activity of caspase-8, but did partially decrease
caspase-3 activity. Finally, the z-IETD-fmk caspase-8
inhibitor also clearly decreased caspase-3 activity in
Response of apoptosis-related proteins to hypoxia Figure 4
Response of apoptosis-related proteins to hypoxia. Western 
blot analysis of 686Tu (Tu) or 686Ln (Ln) cell extracts (30 µg 
each lane) after 24 or 48 hours of hypoxia (H) or normoxia 
(N) treatment. A: Cleavage of procaspase-3 (32 kD) into a 20 
and 11 kD species; B: Cleavage of procaspase-8 (55 kD) into 
the 32 kD product (23 kD product not shown); C: Cleavage 
of procaspase-9 (47 kD) into lower mol. weight products; D: 
Processing of PARP (113 kD) into the typical 89 kD protein 
and a lower molecular weight product (not shown); E: cyto-
chrome C (15 kD) release into cytosolic fraction; F: Re-prob-
ing for β-actin as an internal loading control. Data are 
representative of at least two independent experiments with 
similar results.
Response of apoptosis-related proteins to hypoxia Figure 5
Response of apoptosis-related proteins to hypoxia. Western 
blot analysis of 1386Tu (Tu) or 1386Ln (Ln) cell extracts (30 
µg each lane) after 24 or 48 hours of hypoxia (H) or nor-
moxia (N) treatment. Other legend details are as for Figure 
4.Molecular Cancer 2004, 3:38 http://www.molecular-cancer.com/content/3/1/38
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Hypoxia-stimulated caspase activities in 686 oral cancer cells Figure 6
Hypoxia-stimulated caspase activities in 686 oral cancer cells. The 686Tu (open bars) and 686Ln (closed bars) cells were 
exposed to hypoxia or normoxic control growth for 24 or 48 hours, and induction of caspase activities were assayed as 
described in Materials & Methods. A: caspase-1; B: caspase-3; C: caspase-8; D: caspase-9; E: caspase-10. The means ± S. D. of 
three independent experiments are shown.Molecular Cancer 2004, 3:38 http://www.molecular-cancer.com/content/3/1/38
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addition to the target caspase. These data showed that
both caspase-8 and caspase-9 contribute to the overall cas-
pase-3 activity during hypoxic cell growth, and that those
are the main caspases involved in hypoxia-mediated
Hypoxia-stimulated caspase activation in 1386 oral cancer cells Figure 7
Hypoxia-stimulated caspase activation in 1386 oral cancer cells. The 1386Tu (open bars) and 1386Ln (closed bars) were ana-
lyzed; other legend details are as for Figure 6.Molecular Cancer 2004, 3:38 http://www.molecular-cancer.com/content/3/1/38
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apoptosis activation pathways of these oral cancer cells.
They suggest that both caspase-8 and caspase-9 activation
pathways contributed to the activation of the major execu-
tioner caspases, such as caspases-3 and possibly caspase-7.
Discussion
The aim of this study was to identify factors which con-
tribute to hypoxia-induced cell death in human oral can-
cer cells. The involvement of caspase pathways in
induction of apoptosis of oral cancer cells during hypoxia
was not previously determined. In the present study, we
provide novel evidence for the participation of both initi-
ator and effector caspases in this process (Figure 9). We
showed that exposure to hypoxia elicits apoptotic cell
death, and that this process relies on both intrinsic (mito-
chondrial) and also extrinsic (cell death receptor
Prevention of hypoxia-stimulated caspase activities by intracellular caspase inhibitors Figure 8
Prevention of hypoxia-stimulated caspase activities by intracellular caspase inhibitors. The 686Tu (open bars) and 686Ln 
(closed bars) cells were grown under hypoxia for 48 hours in the presence of different cell-permeable caspase inhibitors, and 
caspase activities were assayed as described in Materials & Methods. A: caspase-3 activity; B: caspase-8 activity; C: caspase-9 
activity. The vertical dashed columns represent cell growth in the presence of the following caspase inhibitors: z-DEVD-fmk, 
caspase-3; z-VAD-fmk, pan-caspase; z-LEHD-fmk, caspase-9; z-IETD-fmk, caspase-8. The means ± S. D. of three independent 
experiments are shown.Molecular Cancer 2004, 3:38 http://www.molecular-cancer.com/content/3/1/38
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mediated) pathways. Our data showed that caspase-3, cas-
pase-8, caspase-9, and caspase-10, but not the pro-inflam-
matory caspase-1, are activated during hypoxic growth.
Activation of the executioner caspase-3 can be blocked in
hypoxic cells by inhibitors of upstream caspases 8 or 9
during cell growth. We also observed that hypoxia-medi-
ated apoptosis of oral cancer cells is associated with con-
trolled cytochrome C release from mitochondria,
proteolytic cleavage of PARP, and DNA fragmentation.
Our results are in agreement with data on hypoxia-
induced apoptosis in other cells [28-30]. In line with our
data, others have observed activation of both caspase-9
and caspase-8 following hypoxic stress in animal models
of brain ischemia [31,32]. Studies with caspase-9 knock-
out mice demonstrated that caspase-9 is a critical
upstream activator of the caspase cascade in vivo and may
be essential for the processing of caspase-3 [33,34]. Also,
earlier reports showed that chemical inhibition of cas-
pase-9 protects against hypoxia-mediated effects [17,18].
On the other hand, it was suggested that key elements of
the death receptor pathway are essential for hypoxia-
induced apoptosis. The extrinsic pathway of apoptosis is
initiated by death ligands, such as the Fas ligand or TRAIL
(TNF-α related apoptosis inducing ligand), leading to the
activation of caspase-8 and caspase-3 [35,36]. Recent
studies indicate that DISC (Death Inducing Signaling
Complex) formation precedes formation of Fas surface
clusters, and that such clustering is dependent on DISC-
generated active caspase-8 [37]. Also, TRAIL can induce
receptor-mediated cell death selectively in tumor cells and
is not active in non-malignant cells [38,39]. It was shown
previously that in some tumor cells, only the receptor-
independent mitochondrial pathway is activated during
hypoxia without caspase-8 involvement [4]. On the other
hand, there is recent evidence that TRAIL receptor-medi-
ated apoptosis induction can be maintained and func-
tional during hypoxic growth of tumor cells [39]. In view
of the equal contribution of the caspase-8 and caspase-9
pathways established here, future work needs to examine
the detailed mechanisms of receptor-mediated caspase
activation with respect to TRAIL and death receptor-DISC-
caspase-8 cascade, as well as the mitochondria-cyto-
chrome C-caspase-9 cascade, and the possible
involvement of HIF-1α as activator of caspases in OSCC
cells. It was reported that hypoxia can induce upregula-
tion of cell death receptors or death receptor ligands [40],
and that inhibition of caspase-8 or FADD may interfere
with hypoxia-induced apoptosis [18,41]. Our data also
suggest that the activator caspase-8 is an integral compo-
nent of the cell death-inducing mechanism in oral cancer
cells, in agreement with other studies [32]. In receptor-
mediated apoptosis, activation of caspase-8 represents a
point of commitment to cell death. Thus, our data clearly
show that in oral carcinoma cells two types of pathways
are activated (Figure 9).
Hypoxia-induced caspase-3 activation and DNA fragmen-
tation have been described by others recently [42,43], as
well as caspase activation accompanying cytochrome C
release from mitochondria [28-30]. Such findings
correlate well with our studies showing that caspases-3, -
8, and -9 activity and expression was significantly higher
in hypoxic than in normoxic cells, and similar caspase
activation was observed in the hypoxic cerebral cortex of
newborn piglets [34]. In our cell system, PARP cleavage
was observed within 24 h of hypoxia treatment and was
accompanied by the appearance of a ~11 kD procaspase-
3 cleavage product, suggesting activation of caspase-3.
Caspase-3 is an executioner caspase that can be activated
by a mitochondrial pathway involving release of cyto-
chrome C [44]; alternatively, caspase-3 can also be acti-
vated by caspase-8 [45,46]. The results of the present
study indicate that hypoxia-induced cleavage of procas-
pase-3 appears to be mediated by both caspase-9 and cas-
pase-8 pathways.
Although cleavage of procaspase-9 was evident as early as
20 h into hypoxia treatment, it is possible that its activa-
tion is mediated by other caspases at earlier time points.
Currently, possible involvement of other Bcl-2 family of
apoptosis regulating proteins (e.g. Bad, Bag, Bak, Bik, etc.)
in hypoxia-induced activation of the mitochondrial
caspase cascade cannot be ruled out. The key regulator of
hypoxia-induced cellular response is believed to be
hypoxia inducible factor 1 (HIF-1). For all cell lines used
here, we observed recently that there were several-fold
increases in HIF-1α expression during hypoxia compared
to normoxia (Wickramasinghe N, Banerjee K, Nagaraj N,
Vigneswaran N and Zacharias W, manuscript submitted).
HIF-1 can initiate apoptosis by inducing pro-apoptotic
proteins such as BNIP3 or NIX, which will inhibit Bcl anti-
apoptotic activity. It can also cause stabilization of wild-
type p53 tumor suppressor, an effect that is lost in cells
with pre-existing p53 mutations [26,47]. On the other
hand, anti-apoptotic proteins, such as IAP-2, can be
induced during hypoxia, whereas the pro-apoptotic pro-
tein Bax can be downregulated, leading to decreased accu-
mulation of Bax in the mitochondria and thus decreased
mitochondrial leakage and cytochrome C release [26,48].
It is apparent that during hypoxia, an intricate balance
exists between factors that induce or counteract apoptosis,
or even stimulate proliferation. More detailed studies are
needed to define the precise mechanism for hypoxia-
induced cleavage of procaspase-9 and procaspase-8;
however, our results clearly demonstrate involvement of
both caspase-8 and caspase-9 in hypoxia-mediated cleav-
age of caspase-3 and PARP. Because caspase-3 is a criticalMolecular Cancer 2004, 3:38 http://www.molecular-cancer.com/content/3/1/38
Page 10 of 14
(page number not for citation purposes)
Potential pathways leading to apoptosis induction during hypoxia treatment Figure 9
Potential pathways leading to apoptosis induction during hypoxia treatment. Hypoxia-induced apoptosis in oral carcinoma cell 
lines relies on both intrinsic (mitochondrial pathways) and also extrinsic (cell death receptor mediated) pathways. Key steps 
are activation of procaspase-8 or procaspase-9, then procaspase-3, and the subsequent cleavage of PARP by activated caspase-
3, resulting in the induction of apoptosis.Molecular Cancer 2004, 3:38 http://www.molecular-cancer.com/content/3/1/38
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mediator of apoptosis [49] and correlates with the onset
of apoptosis in oral cancer cells, it may be a potential
marker for predicting response or resistance to chemo-
therapeutic agents in oral cancer.
The detailed temporal and spatial relationship of these
events to other components of the apoptotic pathway
including downstream caspases remain to be determined.
Recently, the targeted elimination of oral squamous cell
carcinoma cells by inducing apoptosis has emerged as a
valued strategy to combat oral cancer [50]. Increased
mitochondrial permeability is a crucial event in many
types of chemotherapy-induced apoptosis and leads to
release of cytochrome C from the mitochondrial
intermembrane space. Our study confirmed that the
release of cytochrome C was actually augmented during
hypoxic growth, indicating a possible role of cytochrome
C in hypoxia-mediated apoptosis. However, it also has
been reported that certain anticancer drugs induce apop-
tosis in oral cancer cells but do not trigger cytochrome C
release, thereby suggesting that cytochrome C can be an
inducer-dependent phenomenon [51].
In some of the caspase cleavage assays, slightly lower
activities were found for the metastatic Ln cells compared
to the corresponding primary Tu cells. Also, the final
appearance of nucleosomal DNA ladders is much more
pronounced in both Tu cells than in their Ln counterparts.
Although some of those differences were only minor, they
are in line with previous studies which demonstrated
much higher resistance of metastatic OSCC lines to
TRAIL-induced cell death [38] and also to TNF-α-induced
apoptosis [52] than their corresponding primary tumor
lines. Such differential apoptosis sensitivity has also been
observed recently in a different matched cell line pair
form head & neck primary and metastatic carcinoma
(UMSCC101A versus UMSCC101B; unpublished obser-
vations from this lab). On the other hand, a very apparent
difference among the four cells is that caspase-8 activity is
in general several-fold higher in the 686Tu/Ln pair than in
the 1386Tu/Ln pair, which presumably is a reflection of
the different pathologic histories of the two patients from
which the respective tumor tissues were derived.
Conclusions
In summary, we have reported that hypoxia directs apop-
tosis through mitochondria and cell death receptor medi-
ated signaling pathways in oral cancer cells. We believe
that this is the first report on caspase-dependent mecha-
nisms during hypoxia in human oral cancer cells. Expo-
sure to hypoxia lead to the activation of procaspase-9, -8,
-3, and -10, cytochrome C release from mitochondria,
with subsequent cleavage of PARP by activated caspase 3,
finally resulting in the induction of apoptosis. The
detailed molecular and sequential mechanisms of such
hypoxia-induced caspase activation leading to apoptosis
need further investigation. However, the knowledge of the
relevant signaling cascades participating in this process
can provide important insights in the mechanisms of
acquired apoptotic deficiencies during malignant progres-
sion in poorly oxygenated oral carcinomas. It is well
established that poor oxygenation of solid tumors is
associated with poor prognosis. This may not only be due
to direct effects of hypoxia on the efficacy on certain
tumor treatment modalities, but also due to the evolve-
ment of resistant tumor cells during the ontogenesis of a
tumor under hypoxic conditions [39]. Our novel evi-
dence, showing that hypoxia can induce apoptosis
through both pathways, will assist in designing more effi-
cient combination chemotherapy approaches as promis-
ing strategy for the treatment of oral cancers.
Methods
Cell lines
MDA-686Tu (686Tu) and MDA-686Ln (686Ln) cell lines
were derived concurrently from the primary tumor and
lymph node metastasis, respectively, of OSCC involving
the left tonsillar fossa and posterior portion of the tongue
in a 49 year old man (tumor stage T3N3B). MDA-1386Tu
(1386Tu) and MDA-1386Ln (1386Ln) cell lines were
obtained from the primary tumor and lymph node metas-
tasis, respectively, of a 71 year old male patient with
primary hypopharynx tumor (tumor stage T4N3B). All
cell lines were generous gifts from Dr Peter Sacks, New
York University, New York [23]. The cell lines were rou-
tinely maintained in DMEM/F12 50/50 mix (Cambrex
BioScience, Walkersville, MD) containing 10% fetal
bovine serum and 0.4 µg/ml hydrocortisone at 37°C with
5% CO2. All protocols for the use of human cell lines in
this work were approved by the Institutional Review
Boards of The University of Louisville and the University
of Texas at Houston.
Hypoxia exposure
Hypoxic conditions were produced by placing logarithmic
phase subconfluent monolayer cultures, grown on 100
mm dishes, in a modular incubator chamber and
equilibrating for 30 minutes with humidified gas contain-
ing 1 % oxygen, 5 % CO2 and 94 % nitrogen. The cell lines
were maintained under hypoxic conditions for periods of
24 or 48 hours. Control cells were grown in normal oxy-
gen conditions for the same duration. After incubation,
media collection and cell harvesting were done immedi-
ately within 2–3 minutes to avoid adaptation of the cells
to re-oxygenation.
Cell viability assays
Determination of cell viability was done by Trypan Blue
dye exclusion assay. Cells were grown in six-well plates (2
× 104 cells/well) in 3 ml medium to 70 % confluence, thenMolecular Cancer 2004, 3:38 http://www.molecular-cancer.com/content/3/1/38
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washed and treated for hypoxia in DMEM/F12 medium
with 10 % fetal bovine serum. For viability counting, cul-
tures containing both dead and live cells from each well
were collected, centrifuged, and resuspended in 0.5 ml
FBS-free DMEM/F12. An aliquot of 0.1 ml was taken and
incubated with 0.1 ml of Trypan Blue dye (0.4 %) for 5
min. Both live (unstained) and dead (blue) cells were
counted in triplicate measurements from randomly
selected fields in a hemocytometer.
Protein extractions and Western blotting
Cultured cells were rinsed with PBS, gently scraped into 1
ml of PBS, and centrifuged at 4,000 rpm for 3 min. The
pellets were resuspended into RIPA buffer (10 mM Tris-
HCl, pH 7.4, 150 mM NaCl, 1 % Triton X-100, 0.1 % SDS,
and 1 mM EDTA) containing fresh protease inhibitors
(0.5 mM phenylmethylsulfonyl fluoride, 10 µg/ml
aprotinin, and 2 µg/ml of both leupeptin and pepstatin)
(all from Sigma, St. Louis, MO). Then, cell extracts were
sonicated (Model 550 Sonic Dismembrator, Fisher Scien-
tific, Pittsburgh, PA) for 1 min (1.0 sec on/0.5 sec off
pulses) and cell debris was removed by centrifugation.
Proteins were quantified using the Bradford protein assay
kit (Bio-Rad, Hercules, CA) and compared with a γ-globu-
lin standard curve. Equal amounts of total proteins were
separated on a SDS-polyacrylamide gel and transferred
onto a nitrocellulose membrane by electroblotting over-
night at 20 V. Membranes were blocked in TBS-T (10 mM
Tris-HCL, 150 mM NaCl, 0.25 % Tween 20, pH 7.5) with
5 % fat-free powdered milk at room temperature for 1 h.
After rinsing membranes in TBS-T, the following primary
antibodies were used: rabbit polyclonal IgGs for caspase-
3 (H-277), poly(ADP-ribose) polymerase (PARP) (H-
250), caspase-8 (H-134), caspase-9 (H-170) (all from
Santa Cruz Biotechnology, St. Cruz, CA), or mouse mon-
oclonal β-actin antibody (Sigma, St. Louis, MO). After
incubation overnight at 4°C or 1 h at room temperature,
the membranes were washed four times, 10 min each, in
TBS-T. Secondary antibodies used were either horseradish
peroxidase-conjugated goat anti-rabbit IgG or goat anti-
mouse IgG (ICN, Costa Mesa, CA), followed by five
washes with TBS-T. Bands were detected using the
enhanced chemiluminescence ECL substrate (Amersham
Biosciences, Piscataway, NJ). For β-actin detection, previ-
ously probed membranes were soaked in stripping buffer
(70 mM Tris-HCl, pH 6.8, 2 % SDS, 0.1 % β-mercaptoeth-
anol) at 60°C for 30 min and incubation as above.
Caspase assays
After hypoxia treatment for 24 or 48-hours, treated and
control cell cultures were rinsed once in cold PBS and col-
lected in cold PBS by scraping. After centrifugation and
removal of PBS, cell pellets were kept at -80°C until cas-
pase assays were performed. The frozen pellets were resus-
pended in caspase lysis buffer (10 mM HEPES, pH 7.4, 2
mM EDTA, 0.1 % CHAPS) supplemented with protease
inhibitors (5 mM dithiothreitol, 1 mM phenylmethylsul-
fonyl fluoride, 10 µg/ml pepstatin A, 10 µg/ml aprotinin,
and 20 µg/ml leupeptin). Freeze-thaw cell lysis cycles were
performed by alternatively transferring the samples from
an ethanol/dry ice bath to a 37°C water bath five times.
The supernatant was collected after 20 min of
centrifugation at 12,000 rpm in a cold microcentrifuge.
Assays were performed in caspase buffer (10 mM PIPES,
pH 7.4, 2 mM EDTA, 0.1 % CHAPS, 5 mM dithiothreitol),
to which 50 µM of substrate and 5 µl of protein extract
were added to yield a final volume of 100 µl. Peptide sub-
strates for caspase-3, N-acetyl-Asp-Glu-Val-Asp-AFC
(DEVD-AFC), caspase-1, N-acetyl-Tyr-Val-Ala-Asp-AFC
(YVAD-AFC), caspase-8, N-acetyl-Ile-Glu-Thr-Asp-AMC
(IETD-AMC), caspase-9, N-acetyl-Leu-Glu-His-Asp-AFC
(LEHD-AFC) (Biomol, Plymouth Meeting, PA) and cas-
pase-10, N-acetyl-Ala-Glu-Val-Asp-AFC (AEVD-AFC)
(Alexis, San Diego, CA) were dissolved in dimethyl sulfox-
ide. The respective specific inhibitors N-acetyl-Asp-Glu-
Val-Asp-CHO (DEVD-CHO), N-acetyl-Tyr-Val-Ala-Asp-
CHO (YVAD-CHO), N-acetyl-Ile-Glu-Thr-Asp-CHO
(IETD-CHO), N-acetyl-Leu-Glu-His-Asp-CHO (LEHD-
CHO) (Biomol), and N-acetyl-Ala-Glu-Val-Asp-CHO
(AEVD-CHO) (Alexis, San Diego, CA) were used in con-
trol assay reactions. Assays were performed in black-wall,
clear bottom plates using a Spectramax Gemini XS
Microplate Spectrofluorometer (Molecular Devices); read-
ing was at 500 nm after excitation at 405 nm for 7-amino-
4-trifluoromethylcoumarin (AFC) and at 380 nm after
excitation at 460 nm for 7-amino-4-methylcoumarin
(AMC). The results were compared against AFC and AMC
standard curves generated in parallel. Specific activity was
expressed as units, with 1 unit defined as AFC or AMC
release of 1 nMol/hour/µg protein.
Cytochrome C release assays
Cells were collected at the indicated times and washed
once in ice cold PBS. Cell pellets were resuspended in
cytosol extraction buffer, and cytosolic extracts were pre-
pared by the method described previously [24]. Western
blotting for cytochrome C was done with mouse
monoclonal anti-cytochrome C IgG (BD Biosciences-
Pharmingen, San Diego, CA) as described above; the
absence of intra-mitochondrial proteins was verified by
blotting for mitochondrial cytochrome oxidase with
mouse monoclonal anti-cytochrome oxidase IgG (BD
Biosciences-Pharmingen, San Diego, CA).
Hypoxic growth in presence of caspase inhibitors
Oral cancer cells 1386 and 686 were exposed to hypoxia
for 48 hours in the presence or absence of individual cell-
permeable inhibitors for caspase-3 (z-DEVD-fmk; 10
µM), caspase-8 (z-IETD-fmk; 20 µM), caspase-9 (z-LEHD-
fmk; 20 µM), or pan-caspase (z-VAD-fmk; 10 µM) (allMolecular Cancer 2004, 3:38 http://www.molecular-cancer.com/content/3/1/38
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Santa Cruz Biotechnology, Santa Cruz, CA), and proc-
essed for caspase activity assays as above.
Analysis of DNA fragmentation
Apoptotic cells were detected by in situ TdT-mediated
dUTP nick end labeling (TUNEL) assays using the In Situ
Cell Death Detection Kit POD, and nucleosomal DNA
fragments detected with the Apoptotic DNA Ladder Kit
(both from Roche, Indianapolis, IN). DNA fragments
were resolved on 2 % agarose gels for visualizations of
apoptosis-indicative DNA ladders.
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